ATE367150T1 - Arzneimittel - Google Patents

Arzneimittel

Info

Publication number
ATE367150T1
ATE367150T1 AT97946111T AT97946111T ATE367150T1 AT E367150 T1 ATE367150 T1 AT E367150T1 AT 97946111 T AT97946111 T AT 97946111T AT 97946111 T AT97946111 T AT 97946111T AT E367150 T1 ATE367150 T1 AT E367150T1
Authority
AT
Austria
Prior art keywords
drug
Prior art date
Application number
AT97946111T
Other languages
English (en)
Inventor
Takehisa Hata
Yuji Tokunaga
Fumio Shimojo
Sumihisa Kimura
Takeo Hirose
Satoshi Ueda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE367150T1 publication Critical patent/ATE367150T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT97946111T 1996-12-06 1997-12-05 Arzneimittel ATE367150T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32661896 1996-12-06

Publications (1)

Publication Number Publication Date
ATE367150T1 true ATE367150T1 (de) 2007-08-15

Family

ID=18189823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946111T ATE367150T1 (de) 1996-12-06 1997-12-05 Arzneimittel

Country Status (17)

Country Link
US (1) US6346537B1 (de)
EP (1) EP0943327B1 (de)
JP (1) JP4284706B2 (de)
KR (1) KR20000057242A (de)
CN (1) CN1149979C (de)
AR (1) AR008927A1 (de)
AT (1) ATE367150T1 (de)
AU (1) AU726451B2 (de)
BR (1) BR9713866A (de)
CA (1) CA2274485C (de)
DE (1) DE69737936T2 (de)
ES (1) ES2286835T3 (de)
HU (1) HU228680B1 (de)
RU (1) RU2197226C2 (de)
TW (1) TW426516B (de)
WO (1) WO1998024418A1 (de)
ZA (1) ZA9710927B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2198858E (pt) 1998-03-26 2011-09-01 Astellas Pharma Inc Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
IL144828A0 (en) * 1999-03-11 2002-06-30 Fujisawa Pharmaceutical Co A pipecolic acid derivative containing liposome composition
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
EP1517682B1 (de) * 2002-06-28 2006-11-02 Speedel Pharma AG Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant
JP2007527383A (ja) * 2003-07-09 2007-09-27 チョン クン ダン ファーマスーティカル コーポレイション タクロリムス固体分散物
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
CA2537041C (en) * 2003-08-29 2012-04-03 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
SI1663217T1 (sl) * 2003-08-29 2010-10-29 Lifecycle Pharma As Trdne disperzije, ki vsebujejo takrolimus
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
CA2615598C (en) * 2005-07-20 2014-04-15 Peter Valent Compositions for treatment of systemic mastocytosis
US7652364B2 (en) * 2005-12-21 2010-01-26 Teradata Us, Inc. Crossing conductive traces in a PCB
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
EP1923053A1 (de) 2006-09-27 2008-05-21 Novartis AG Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
CA2678455C (en) 2007-01-10 2019-02-12 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
KR100868295B1 (ko) * 2007-02-15 2008-11-11 풍림무약주식회사 레플루노미드를 함유하는 고체분산체 및 이의 제조방법
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
SI2167033T1 (sl) 2007-05-30 2017-08-31 Veloxis Pharmaceuticals A/S Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
RU2373926C1 (ru) * 2008-06-06 2009-11-27 Сергей Юрьевич Лешков Композиции, содержащие частицы резвератрола, и способ их получения (варианты)
RU2574006C2 (ru) * 2008-07-08 2016-01-27 Лайфсайкл Фарма А/С Такролимус для улучшенного лечения пациентов с трансплантатами
CN102149715A (zh) * 2008-09-17 2011-08-10 Cj第一制糖株式会社 肝适能的稳定化固态分散物及其制备方法
LT2575769T (lt) * 2010-02-17 2016-10-10 Veloxis Pharmaceuticals A/S Stabilizuota takrolimuzo kompozicija
WO2011116034A1 (en) * 2010-03-17 2011-09-22 Lutran Industries, Inc. Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CN105663092A (zh) * 2016-03-03 2016-06-15 海南华益泰康药业有限公司 一种含有他克莫司固体分散体的缓释胶囊及其制备方法
US11154522B2 (en) 2016-05-26 2021-10-26 Dermala Inc. Compositions and methods for treating acne vulgaris

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
ATE117897T1 (de) 1989-07-05 1995-02-15 Fujisawa Pharmaceutical Co Wässriges flüssiges mittel zur äusserlichen anwendung.
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5817333A (en) 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
JP3520517B2 (ja) 1992-11-18 2004-04-19 藤沢薬品工業株式会社 医薬用持続性製剤
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Also Published As

Publication number Publication date
ZA9710927B (en) 1998-06-15
BR9713866A (pt) 2000-03-14
ES2286835T3 (es) 2007-12-01
EP0943327B1 (de) 2007-07-18
CN1245424A (zh) 2000-02-23
EP0943327A4 (de) 2003-06-25
AU726451B2 (en) 2000-11-09
HU228680B1 (en) 2013-05-28
AU5136998A (en) 1998-06-29
CN1149979C (zh) 2004-05-19
CA2274485A1 (en) 1998-06-11
TW426516B (en) 2001-03-21
JP4284706B2 (ja) 2009-06-24
HUP0000587A1 (hu) 2000-09-28
WO1998024418A1 (fr) 1998-06-11
CA2274485C (en) 2008-02-05
AR008927A1 (es) 2000-02-23
US6346537B1 (en) 2002-02-12
EP0943327A1 (de) 1999-09-22
RU2197226C2 (ru) 2003-01-27
KR20000057242A (ko) 2000-09-15
DE69737936T2 (de) 2007-12-06
DE69737936D1 (de) 2007-08-30
HUP0000587A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
ATE367150T1 (de) Arzneimittel
ATE187063T1 (de) Arzneimittel
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
ID23874A (id) Obat
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
DE69735712D1 (de) Aryl-pyrimidin-derivate
ATE261942T1 (de) 6-phenylpyridinderivate
NO981946D0 (no) Imidazoquinazolin-derivater
DE69732576D1 (de) Tetrahydrobenzindolon-derivate
ID16781A (id) Formulasi-formulasi farmasi
EE9900182A (et) 2-metoksüfenüülpiperasiini derivaadid
EE9800209A (et) Antiglükokortikoidne ravimaine
ID18698A (id) Komposisi farmasi
FI961364L (fi) Lääkeainekoostumus
ITMI962628A0 (it) Composizione farmaceutica
DE59805373D1 (de) Nephroprotektive Arzneimittel
FI965181L (fi) Polyalkoholi-peptidijohdannaiset
NO992244D0 (no) AIDS-legemiddel
SK1380U (sk) Farmaceutický preparát
SE9602895D0 (sv) Intag av mediciner
SE9402131D0 (sv) Läkemedel
SE9401674L (sv) Läkemedel
NO944330D0 (no) Legemiddel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties